Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of DS-7011a in Healthy Participants
NCT05203692Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing DS-7011a with Placebo (2 arms). Primary endpoint: Number of Participants with Treatment-emergent Adverse Events. Started Feb 2022; status: completed.
02
Drugs
DS-7011a
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05203692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203692.